European Commission expands Trodelvy use in metastatic breast cancer
The European Commission expands the role of Gilead’s Trodelvy in first-line metastatic triple-negative breast cancer across PD-L1 status.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.